Stemtech Stock Total Debt
STEK Stock | USD 0.05 0 5.66% |
Stemtech fundamentals help investors to digest information that contributes to Stemtech's financial success or failures. It also enables traders to predict the movement of Stemtech OTC Stock. The fundamental analysis module provides a way to measure Stemtech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Stemtech otc stock.
Stemtech |
Stemtech OTC Stock Total Debt Analysis
Stemtech's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Stemtech Total Debt | 219.47 K |
Most of Stemtech's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Stemtech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition |
Based on the latest financial disclosure, Stemtech has a Total Debt of 219.47 K. This is 99.99% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Stemtech Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Stemtech's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Stemtech could also be used in its relative valuation, which is a method of valuing Stemtech by comparing valuation metrics of similar companies.Stemtech is currently under evaluation in total debt category among its peers.
Stemtech Fundamentals
Return On Asset | -0.75 | |||
Profit Margin | (1.85) % | |||
Operating Margin | (1.34) % | |||
Current Valuation | 8.79 M | |||
Shares Outstanding | 48.63 M | |||
Shares Owned By Insiders | 63.60 % | |||
Price To Sales | 1.54 X | |||
Revenue | 4.32 M | |||
Gross Profit | 3.3 M | |||
EBITDA | 1.58 M | |||
Net Income | (7.08 M) | |||
Cash And Equivalents | 399.73 K | |||
Cash Per Share | 0.01 X | |||
Total Debt | 219.47 K | |||
Current Ratio | 0.03 X | |||
Book Value Per Share | (0.08) X | |||
Cash Flow From Operations | (1.91 M) | |||
Earnings Per Share | 0.10 X | |||
Market Capitalization | 6.52 M | |||
Total Asset | 5.72 M | |||
Z Score | 17.4 | |||
Net Asset | 5.72 M |
About Stemtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Stemtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Stemtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Stemtech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.